Article ; Online: General purpose models for intravenous anesthetics, the next generation for target-controlled infusion and total intravenous anesthesia?
Current opinion in anaesthesiology
2023 Volume 36, Issue 5, Page(s) 602–607
Abstract: Purpose of review: There are various pharmacokinetic-dynamic models available, which describe the time course of drug concentration and effect and which can be incorporated into target-controlled infusion (TCI) systems. For anesthesia and sedation, most ...
Abstract | Purpose of review: There are various pharmacokinetic-dynamic models available, which describe the time course of drug concentration and effect and which can be incorporated into target-controlled infusion (TCI) systems. For anesthesia and sedation, most of these models are derived from narrow patient populations, which restricts applicability for the overall population, including (small) children, elderly, and obese patients. This forces clinicians to select specific models for specific populations. Recent findings: Recently, general purpose models have been developed for propofol and remifentanil using data from multiple studies and broad, diverse patient groups. General-purpose models might reduce the risks associated with extrapolation, incorrect usage, and unfamiliarity with a specific TCI-model, as they offer less restrictive boundaries (i.e., the patient "doesn't fit in the selected model") compared with the earlier, simpler models. Extrapolation of a model can lead to delayed recovery or inadequate anesthesia. If multiple models for the same drug are implemented in the pump, it is possible to select the wrong model for that specific case; this can be overcome with one general purpose model implemented in the pump. Summary: This article examines the usability of these general-purpose models in relation to the more traditional models. |
---|---|
MeSH term(s) | Child ; Aged ; Humans ; Anesthetics, Intravenous/adverse effects ; Anesthesia, Intravenous/adverse effects ; Anesthesia, General ; Propofol/adverse effects ; Remifentanil/adverse effects |
Chemical Substances | Anesthetics, Intravenous ; Propofol (YI7VU623SF) ; Remifentanil (P10582JYYK) |
Language | English |
Publishing date | 2023-08-08 |
Publishing country | United States |
Document type | Review ; Journal Article |
ZDB-ID | 645203-6 |
ISSN | 1473-6500 ; 0952-7907 |
ISSN (online) | 1473-6500 |
ISSN | 0952-7907 |
DOI | 10.1097/ACO.0000000000001300 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 2564: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.